Navigation Links
Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
Date:12/6/2008

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Researchers today report that after the implementation of Medicare coverage limitations for erythropoiesis-stimulating agents (ESAs), a significantly greater proportion of anemic cancer patients who were on chemotherapy and who received ESAs needed blood transfusions and utilized more units of blood per patient than those patients who received ESAs prior to implementation of coverage limitations. The findings from this observational study will be presented at the 50th Annual Meeting of the American Society of Hematology on Saturday, December 6th at 9:00 a.m. PST.

In July 2007, the Centers for Medicare and Medicaid Services (CMS) issued coverage limitations, in the form of a National Coverage Determination (NCD), for the use of ESAs in anemic cancer patients receiving chemotherapy. An ongoing, prospective, observational study [Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) registry] is evaluating ESA-treated anemic cancer patients receiving chemotherapy. The present analyses were conducted using data from this study, focused on patients covered by Medicare before and after implementation of the CMS NCD for ESAs.

"We wanted to examine the potential impacts on transfusion patterns and hematologic changes in anemic Medicare patients receiving chemotherapy treated with ESAs before and after implementation of the ESA coverage limitations," said study director Chris L. Pashos, PhD, Vice President, Abt Bio-Pharma Solutions, Inc. "Our analyses found increased transfusion rates and greater blood utilization in anemic Medicare patients receiving chemotherapy and treated with ESAs after implementation of the ESA NCD compared with before implementation of the ESA NCD."

Study Methods and Results

Data from 288 Medicare patients (pre-NCD: 230, post-NCD: 58) from 41 sites included in the DOSE registry were analyzed. Data we
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
2. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
3. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
4. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
5. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
6. Gene Therapy Corrects Sickle Cell Disease in Laboratory Study
7. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
10. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... 2015  The departments of Drug and Alcohol Programs ... Concept 90 to raise awareness for International Overdose Awareness ... Pennsylvania and help more Pennsylvanians with ... through the Building Bridges to Recovery initiative. ... day to a disease that is fully treatable, if ...
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nurse Scholar-in Residence at the Institute of Medicine (IOM) of the National Academies. ... at Columbia University School of Nursing. A member of the Institute of Medicine ...
(Date:9/1/2015)... ... 01, 2015 , ... Ogawa’s new massage chairs tout innovative functionality that change ... than ever before. With the goal of bringing wellness to the world, Ogawa introduces ... , As in its name, the Ogawa Refresh aims to “refresh” ...
(Date:9/1/2015)... Aventura, Florida (PRWEB) , ... September 01, 2015 ... ... across language barriers and international borders seldom arise at the most convenient time ... which is always ready to help. , Universal Translation Services has ...
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... to send information about new patients directly from Practice Perfect to FOTO enabling ... data entry. , Steven Presement, President of Practice Perfect, stated ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2
... volunteers for HIV/AIDS research in the United States and ... that the forms were extremely long and used wording ... understanding, according to bioethicists at The Johns Hopkins University. ... U.S. government-sponsored, multinational HIV/AIDS research conducted in 2006 revealed ...
... THURSDAY, July 14 (HealthDay News) -- A novel version ... and animals has managed to jump from one species and ... virus is from the adenovirus family, responsible for the common ... now -- unlike other types of viruses -- these particular ...
... July 14, 2011) In a study, Identification of ... in the July 2011 issue of the Journal ... of Dental Medicine found that dental visits represented a ... individuals with diabetes or pre-diabetes who are unaware of ...
... , THURSDAY, July 14 (HealthDay News) -- Military veterans who ... suicide attempt, but have an overall heightened risk of death ... study, published online in BioMed Central Public Health , ... seen at a Veterans Affairs medical center for a suicide ...
... Reporter , WEDNESDAY, July 13 (HealthDay News) -- Top ... air traffic controllers napping on the job are missing ... Studies have shown that short "power naps" have ... for people impaired by drowsiness, said Dr. Alon Avidan, ...
... cost-effective for treating people who are severely obese, but also ... study from Washington University School of Medicine in St. Louis. ... people, the researchers say. Patients who have the surgery ... have fewer medical problems related to their weight, indicating the ...
Cached Medicine News:Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 2Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 2Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 4Health News:Dentists can identify people with undiagnosed diabetes, Columbia researchers show 2Health News:Sometimes Sleeping on the Job May Be a Good Thing 2Health News:Sometimes Sleeping on the Job May Be a Good Thing 3Health News:Weight-loss surgery cost-effective for all obese 2Health News:Weight-loss surgery cost-effective for all obese 3
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
Saline Solution to rinse and store soft contact lenses and for heat disinfection....
Sensitive Eyes Plus Saline Solution to rinse soft contact lenses The unique, gentle, pH-balanced formula contains potassium, an ingredient found in tears....
Medicine Products: